JP2004500895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500895A5 JP2004500895A5 JP2002504687A JP2002504687A JP2004500895A5 JP 2004500895 A5 JP2004500895 A5 JP 2004500895A5 JP 2002504687 A JP2002504687 A JP 2002504687A JP 2002504687 A JP2002504687 A JP 2002504687A JP 2004500895 A5 JP2004500895 A5 JP 2004500895A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gene
- sequence
- accession number
- identified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000012634 fragment Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- 108090000058 Syndecan-1 Proteins 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000003705 Syndecan-1 Human genes 0.000 description 4
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102000018329 Keratin-18 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000010033 lipoblastoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000004333 pleomorphic adenoma Diseases 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21572700P | 2000-06-21 | 2000-06-21 | |
| US24397600P | 2000-10-27 | 2000-10-27 | |
| PCT/US2001/019980 WO2001098539A2 (en) | 2000-06-21 | 2001-06-21 | Gene markers for lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004500895A JP2004500895A (ja) | 2004-01-15 |
| JP2004500895A5 true JP2004500895A5 (enExample) | 2006-05-18 |
| JP4392163B2 JP4392163B2 (ja) | 2009-12-24 |
Family
ID=26910326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504687A Expired - Fee Related JP4392163B2 (ja) | 2000-06-21 | 2001-06-21 | 肺癌用遺伝子マーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7214781B2 (enExample) |
| EP (1) | EP1356093A2 (enExample) |
| JP (1) | JP4392163B2 (enExample) |
| CN (1) | CN1471587A (enExample) |
| AU (1) | AU2001270082A1 (enExample) |
| WO (1) | WO2001098539A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158293A0 (en) | 2001-04-10 | 2004-05-12 | Agensys Inc | Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same |
| EP1510587B1 (en) * | 2002-05-21 | 2011-07-13 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
| GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| US20050186215A1 (en) * | 2004-02-04 | 2005-08-25 | Kwok Tim T. | CUDR as biomarker for cancer progression and therapeutic response |
| JP2009504168A (ja) | 2005-08-17 | 2009-02-05 | メディクシス エス．エー． | Ｃｋ１９発現を確認する組成物及び方法 |
| WO2007092105A1 (en) * | 2006-02-03 | 2007-08-16 | Hill's Pet Nutrition, Inc. | Method for evaluating kidney function in a feline by measuring ghrelin hormone levels |
| WO2007130967A2 (en) * | 2006-05-01 | 2007-11-15 | Siemens Healthcare Diagnostics Inc. | Novel oligonucleotide primers and methods for dna replication |
| KR101443214B1 (ko) | 2007-01-09 | 2014-09-24 | 삼성전자주식회사 | 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이 |
| WO2009043115A1 (en) * | 2007-10-04 | 2009-04-09 | Fermiscan Australia Pty Limited | Method for identifying biomarkers which are diagnostic for a pathological condition |
| JP2013099253A (ja) * | 2010-03-11 | 2013-05-23 | Intec Systems Institute Inc | 肺癌または子宮頸癌の診断マーカー |
| WO2012031374A1 (zh) * | 2010-09-09 | 2012-03-15 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 |
| ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
| MY205689A (en) | 2017-10-02 | 2024-11-06 | Visterra Inc | Antibody molecules to cd138 and uses thereof |
| WO2020007898A1 (en) * | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating brain injury or neurodegenerative disease |
| US12338291B2 (en) * | 2019-06-17 | 2025-06-24 | Visterra, Inc. | Humanized antibody molecules to CD138 and uses thereof |
| KR20210020417A (ko) * | 2019-08-14 | 2021-02-24 | 연세대학교 산학협력단 | 메티오닐-티알엔에이 합성효소 및 판사이토케라틴을 이용한 폐암 진단 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5272057A (en) * | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| ATE345387T1 (de) | 1998-03-18 | 2006-12-15 | Corixa Corp | Verbindungen und verfahren für therapie und diagnose von lungenkrebs |
-
2001
- 2001-06-21 WO PCT/US2001/019980 patent/WO2001098539A2/en not_active Ceased
- 2001-06-21 US US10/297,277 patent/US7214781B2/en not_active Expired - Fee Related
- 2001-06-21 JP JP2002504687A patent/JP4392163B2/ja not_active Expired - Fee Related
- 2001-06-21 CN CNA018115438A patent/CN1471587A/zh active Pending
- 2001-06-21 AU AU2001270082A patent/AU2001270082A1/en not_active Abandoned
- 2001-06-21 EP EP01948623A patent/EP1356093A2/en not_active Withdrawn
-
2005
- 2005-10-19 US US11/255,001 patent/US20060275783A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500895A5 (enExample) | ||
| Myers et al. | Molecular cloning of alpha 5 (IV) collagen and assignment of the gene to the region of the X chromosome containing the Alport syndrome locus | |
| US7807373B2 (en) | Prostate specific gene, PCGEM1, and methods of using PCEGM1 to detect, treat, and prevent prostate cancer | |
| Katoh | Trefoil factors and human gastric cancer | |
| WO1999034004A3 (en) | Metastatic breast and colon cancer regulated genes | |
| WO2003101283A2 (en) | Diagnostics markers for lung cancer | |
| JP2004524810A5 (enExample) | ||
| EP0854923A2 (en) | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis | |
| WO2000022130A3 (en) | Metastatic breast and colon cancer regulated genes | |
| Mighell et al. | Human tenascin‐C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae | |
| WO1999064594A9 (en) | Genes and gene expression products that are differentially regulated in prostate cancer | |
| Schlott et al. | Different gene expression of MDM2, GAGE-1,–2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia | |
| DE69720471D1 (de) | Verfahren zur prognose von prostata krebs | |
| EP1642907A3 (en) | Composition and methods for the diagnosis of tumours | |
| AU3919600A (en) | Prostate-specific gene, pcgem1, and methods of using pcgem1 to detect, treat, and prevent prostate cancer | |
| Peller et al. | p53 mutations in matched primary and metastatic human tumors | |
| EP1370684B1 (en) | Polynucleotides related to colon cancer | |
| JP2011525352A5 (enExample) | ||
| EP1179589A1 (en) | MMX-1, a member of the family of human cancer/testis antigens, a protein encoded thereby and a process for determining whether a tumor sample has metastatic potential | |
| US7105315B2 (en) | Transmembrane protein differentially expressed in cancer | |
| CN100491527C (zh) | 特征在于检测g-csf外显子3缺失的癌症诊断方法 | |
| Van de Vijver | Ductal carcinoma in situ of the breast: histological classification and genetic alterations | |
| Katsaraki et al. | SCAF1 (SR-related CTD-associated factor 1) | |
| EP1062333B1 (en) | Chondrosarcoma associated genes | |
| WO1998042830A3 (en) | Noey2 gene compositions and methods of use |